nobody loves being given the middle finger by those that are no longer invested,so as you only registered this morning and have no track record,we only have your word on that.Not the brightest of openings to begin with,have a good weekend.
This share may perform like PYC, further demise through time with a few spikes here and there. All hope was last early 2013 after the nailed on deal turned out to be false, all RNS's are now taken with a pinch of salt.. Over a 75% loss in 15 months. joke
that SAR is due for a rise in SP very soon. I went from 0.65 - 2.00 not so long ago, so know its possible to happen again. If what stevej says is correct then Monday should see movement upwards in anticipation. GL
Topped up again today in anticipation of SP going back to over 1p soon. It seems to me the MC of £8.55m barely factors in any commercial success of any of the running programmes. As usual, we wait.....
late night's drinking and lots of presentations during the day; a draining experience - on a bit of a sausage and pils detox now (so to speak).
A reminder from the house broker report post the update at the end of Feb, for what it is worth.
"In 2014, we expect further news of progress in all the four lead projects. There is the possibility of further news on the TYK2 project, with development partner, SRI, publishing pre-clinical data on its psoriasis study, which the Sareum management is hoping to present in conferences during 2014. SRI’s studies have also indicated that Sareum’s lead compounds are inhibiting JAK1 which, like TYK2, is another member of the JAK family of kinases and is essential for signaling by a number of cytokines involved in psoriasis, as well as inflammatory bowel disease and rheumatoid arthritis. Sareum’s compounds will be tested on models of these diseases in due course.
The first half of 2014, we may also see news of Aur+FLT3 being granted an EU patent and the release of pre-clinical data from the FASN study, funded by a TSB Biomedical Catalyst grant.
In the second half of 2014, we expect the TYK2 project to nominate a lead candidate. Studies on the CHK1 inhibitor candidates continue to focus on completing the pre-clinical development phase of the programme, which include demonstrating control of the production of the candidate molecule and an assessment of its safety profile. If successful, it will lead to the submission of a clinical trial application to the UK regulator, MHRA, in late 2014/early 2015. If this is approved, the first-in-human trials in cancer patients would then be initiated."
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.